Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Queensland Health
Fish and Richardson
McKesson
US Department of Justice
Colorcon
Farmers Insurance
Express Scripts

Generated: July 22, 2018

DrugPatentWatch Database Preview

Baxter Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for BAXTER HLTHCARE, and what generic alternatives to BAXTER HLTHCARE drugs are available?

BAXTER HLTHCARE has one hundred and ninety-three approved drugs.

There are five US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.

There are eighty-seven patent family members on BAXTER HLTHCARE drugs in thirty-two countries and one hundred and sixty-one supplementary protection certificates in twelve countries.

Summary for Baxter Hlthcare
International Patents:87
US Patents:5
Tradenames:303
Ingredients:110
NDAs:193

Drugs and US Patents for Baxter Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER amino acids; dextrose INJECTABLE;INJECTION 019520-005 Sep 23, 1988 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Baxter Hlthcare NALLPEN IN PLASTIC CONTAINER nafcillin sodium INJECTABLE;INJECTION 050655-001 Oct 31, 1989 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Baxter Hlthcare MESNEX mesna TABLET;ORAL 020855-001 Mar 21, 2002 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Baxter Hlthcare VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER vancomycin hydrochloride INJECTABLE;INJECTION 050671-002 Dec 20, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Baxter Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare BREVIBLOC IN PLASTIC CONTAINER esmolol hydrochloride INJECTABLE;INJECTION 019386-004 Feb 16, 2001 4,593,119*PED ➤ Try a Free Trial
Baxter Hlthcare ETHRANE enflurane LIQUID;INHALATION 017087-001 Approved Prior to Jan 1, 1982 3,527,813 ➤ Try a Free Trial
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 4,882,452 ➤ Try a Free Trial
Baxter Hlthcare EXTRANEAL icodextrin SOLUTION;INTRAPERITONEAL 021321-001 Dec 20, 2002 6,248,726 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Inhalation 99.90% ➤ Subscribe 2008-09-11
➤ Subscribe Injection 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags ➤ Subscribe 2014-01-31

Non-Orange Book US Patents for Baxter Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,410,077 Sulfoalkyl ether cyclodextrin compositions ➤ Try a Free Trial
9,750,822 Sulfoalkyl ether cyclodextrin compositions ➤ Try a Free Trial
9,200,088 Sulfoalkyl ether cyclodextrin compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/028 United Kingdom ➤ Try a Free Trial PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
2014000088 Germany ➤ Try a Free Trial PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912
C/GB04/034 United Kingdom ➤ Try a Free Trial PRODUCT NAME: PREGABALIN (S-(+)-4-AMINO-3(2-METHYLPROPYL)BUTANOIC ACID) OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACTIVE SALT.; REGISTERED: UK EU/1/04/279/001 20040706; UK EU/1/04/279/002 20040706; UK EU/1/04/279/003 20040706; UK EU/1/04/279/004 20040706; UK EU/1/04/279/005 20040706; UK EU/1/04/279/006 20040706; UK EU/1/04/279/025 20040706; UK EU/1/04/279/019 20040706; UK EU/1/04/279/020 20040706; UK EU/1/04/279/021 20040706; UK EU/1/04/279/022 20040706; UK EU/1/04/279/023 20040706; UK EU/1/04/279/024 20040706; UK EU/1/04/279/013 20040706; UK EU/1/04/279/014 20040706; UK EU/1/04/279/015 20040706; UK EU/1/04/279/016 20040706; UK EU/1/04/279/017 20040706; UK EU/1/04/279/018 20040706; UK EU/
073 Luxembourg ➤ Try a Free Trial PRODUCT NAME: ACIDE BENZOIQUE 3-{6-{-1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBONYL AMINO}-3-METHYLPYRIDIN-2-YL}, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, OU UN PRO-MEDICAMENT DE TYPE ESTER DE CELUI-CI; FIRST REGISTRATION DATE: 20151124
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Argus Health
Accenture
Federal Trade Commission
Harvard Business School
Cantor Fitzgerald
Mallinckrodt
Teva
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.